

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



D1
✓

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification: C12N 15/31, 5/10, C12P 21/02, A01N 63/02		A1	(11) International Publication Number: WO 95/00647
			(43) International Publication Date: 5 January 1995 (05.01.95)
(21) International Application Number: PCT/AU94/00348		(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 24 June 1994 (24.06.94)			
(30) Priority Data: PL 9638 25 June 1993 (25.06.93) AU			
(71) Applicant (for all designated States except US): COMMON-WEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION [AU/AU]; Limestone Avenue, Campbell, ACT 2601 (AU).		Published With international search report. With amended claims.	
(72) Inventors; and (75) Inventors/Applicants (for US only): SMIGIELSKI, Adam, Joseph [AU/AU]; 23 Jarrah Street, O'Connor, ACT 2601 (AU). AKHURST, Raymond, Joseph [AU/AU]; 17 Burara Crescent, Waramanga, ACT 2611 (AU).			
(74) Agent: F.B. RICE & CO.; 28a Montague Street, Balmain, NSW 2041 (AU).			
(54) Title: TOXIN GENE FROM XENORHABDUS NEMATOPHILUS			
(57) Abstract Purified insecticidal toxins and biologically active fragments thereof, and polynucleotide molecules encoding same, from the bacteria <i>Xenorhabdus nematophilus</i> are described.			

TOXIN GENE FROM XENORHABDUS NEMATOPHILUS**Technical Field**

The present invention concerns the identification and isolation of a new class of protein toxins specific against insects which are produced by bacteria from the species *Xenorhabdus nematophilus* and possibly by the species *X.beddingii*. In addition, the present invention relates to the insertion of this class of toxin into recombinant viruses, bacteria, protozoa, fungi, and transgenic plants in order to broaden the use of these toxins for control of a large range of insect pests and plant parasitic nematodes.

Background

Insect pathogenic nematodes of the family *Steinernematidae* are known to be symbiotically associated with bacteria of the genus *Xenorhabdus*. It has been observed that these bacteria have the ability to kill a wide range of different insects without the aid of their nematode partners.

The present inventors have identified a new class of toxins. A DNA fragment encoding one of these toxins has been isolated from *Xenorhabdus nematophilus* strain A24 and characterised by sequencing. As will be recognised by persons skilled in the art, DNA fragments encoding members of this new class of toxins may be usefully introduced into viral agents, including entomopox and nuclear polyhedrosis viruses; bacteria (including *Gracilicutes*, *Firmicutes*, *Tenericutes* and *Mendosicutes*); fungi; protozoa; and plants.

Summary of the Present Invention

In a first aspect, the present invention consists in a polynucleotide molecule comprising a nucleotide sequence which encodes an insecticidal toxin and which is at least 70% homologous to the nucleotide sequence shown in Table 1 from residue 83 to 919, or a fragment thereof which fragment encodes an insecticidal polypeptide.

In a preferred embodiment of the present invention the nucleotide sequence is at least 90% to the sequence shown in Table 1 from residue 83 to 919.

Preferably, the nucleotide sequence which encodes an
5 insecticidal toxin from *Xenorhabdus* and more preferably, the nucleotide sequence substantially corresponds to the sequence shown in Table 1 from residue 83 to 919.

In a second aspect the present invention provides in an insecticidal toxin which includes an amino acid
10 sequence which is at least 70% homologous to residues 1 to 278 shown in Table 2 or a functional fragment thereof.

In a preferred embodiment of the present invention the insecticidal toxin includes an amino acid sequence which is at least 90% homologous to residues 1 to 278
15 shown in Table 1 or a functional fragment thereof.

In a further preferred embodiment the insecticidal toxin includes an amino acid sequence substantially corresponding to residues 1 to 278 in Table 1 or a functional fragment thereof.

20 In a third aspect the present invention provides in a recombinant organism, the organism being characterised in that it is transformed with the polynucleotide molecule of the first aspect of the present invention.

The organisms which may be usefully transformed with
25 the polynucleotide molecule of the first aspect of the present invention include viral agents such as entomopox and nuclear polyhedrosis viruses; bacteria, such as *Gracilicutes*, *Firmicutes*, *Tenericutes* and *Mendosicutes*; fungi; protozoa; and plants.

30 The term "substantially corresponds" as used herein in relation to the nucleotide sequence is intended to encompass minor variations in the nucleotide sequence which due to degeneracy do not result in a change in the encoded protein. Further this term is intended to
35 encompass other minor variations in the sequence which may be required to enhance expression in a particular system

but in which the variations do not result in a decrease in biological activity of the encoded protein.

The term "substantially corresponding" is used herein in relation to the amino acid sequence is intended to encompass minor variations in the amino acid sequence which do not result in a decrease in biological activity of the insecticidal toxin. These variations may include conservative amino acid substitutions. The substitutions envisaged are:-

10 G, A, V, I, L, M; D, E; N, Q; S, T; K, R, H; F, Y, W, H; and P, α -alkalamino acids.

As used herein the term "functional fragments" is intended to encompass fragments of the insecticidal toxin which retain insecticidal activity.

15 In a fourth aspect, the present invention provides a method for controlling the proliferation of insects, comprising applying to an infested area a recombinant organism according to the third aspect optionally in admixture with an acceptable agricultural carrier.

20 Isolation and Characterisation of a Toxin from *Xenorhabdus nematophilus* A24
Generation of a Cosmid Library

Genomic DNA from *Xenorhabdus nematophilus* A24, isolated using the method of Marmur (1961) was
25 partially digested using the restriction enzyme Sau 3A, to generate fragments of DNA that were in the size range of 30 to 50 kilobasepairs (kb), and dephosphorylated using the enzyme calf alkaline phosphatase. The cosmid "Supercos" (Stratagene) was prepared to receive foreign
30 insert DNA into its Bam HI cloning site according to the manufacturer's instructions. The digested DNA from *X.nematophilus* A24 was added to the cosmid DNA in a ratio of 3:1 and ligated together using the enzyme T4 DNA
ligase. The ligated material was subsequently packaged
35 into λ -bacteriophage using the Gigapack II XL Packaging Extract (Stratagene) as per the manufacturer's

instructions. The packaged DNA was subsequently transfected into the *Escherichia coli* strain NM554 (F-, recA, araD139, Δ (ara, leu) 7696, Δ lac Y74, galU-, galK-, hsr, hsm⁺, strA, mcrA[-], mcrB[-]. Bacteria were plated
5 out onto Luria Bertani (LB) agar plates containing 150 μ g ml⁻¹ ampicillin to select for those bacteria containing recombinant Supercos plasmids.

Screening for Toxin Producing Clones

Individual clones were grown overnight at 28°C in LB
10 containing 150 μ g ml⁻¹ ampicillin. Cultures were treated for 15 minutes with 2mg ml⁻¹ lysozyme in order to release any proteins produced by the recombinant DNA into the medium. Five μ l aliquots of this solution were then injected directly into the haemocoel of three *Galleria mellonella*
15 fourth instar larvae. Appropriate controls containing lysozyme and non-recombinant *E.coli* NM554 cultures were also injected to confirm the absence of any toxicity to these larvae. Two clones were found to have strong insecticidal activity. Injected larvae were found
20 to be very sluggish after 30 hours, with all larvae dead within three days.

Characterisation of Toxin Producing Clones

The recombinant Supercos DNA from these clones was isolated using an alkaline lysis procedure (Maniatis et
25 al., 1982). Isolated DNA was digested with varying restriction enzymes and analysed using TAE agarose gel electrophoresis (Maniatis et al, 1982). It was found that both clones were identical and contained a 34.6 kb DNA insert from *X. nematophilus* A24. One of these clones
30 cos149 was chosen for further study.

A 7.4kb Bam HI fragment from cos149 was cloned into the plasmid vector pGEM7Z(f)+ (Promega) which was transformed into the *E.coli* strain DH5 α (F-, Φ 80dlac Z Δ M15, recA1, endA1, gyrA96, thi-1, hsdR17[r⁻, m⁺] sup
35 E44, relA1, deoR, Δ [lacZYA-argF] U169) using electroporation at 25 μ F, 200 Ω and 2.5kV in a 0.2cm

cuvette in a Bio-Rad Gene Pulser. This clone (N8pGEM) was found to continue to be toxic against *G.mellonella* larvae.

Plasmid DNA from N8pGEM was isolated and digested with the restriction enzymes ClaI and SphI. This resulted in the linearization of this plasmid containing one end (3') which was resistant to digestion by the enzyme Exonuclease III and the other end (5') which could be digested at a constant rate of 450 bases per minute at 37°C by this enzyme using the Erase-a-Base kit from Promega. Using this enzyme aliquots containing decreasing size plasmids were obtained which were recircularised using the enzyme T4 DNA ligase. Recircularised plasmids were reintroduced into the bacterium *E.coli* strain DH5a using electroporation (see above). Varying size clones were selected and used for injecting *G.mellonella* larvae. The smallest clone which continued to be insecticidal was found to contain 1.5kb of *X.nematophilus* A24 DNA and was designated tox 1.

Plasmid DNA from tox 1 was isolated and digested with the restriction enzymes Sac I and HindIII, respectively to again create linear molecules with one end resistant and the other sensitive to digestion with Exonuclease III. Deletion mutants were isolated and tested against *G.mellonella* larvae. A clone which now only contained 1.2kb of *X.nematophilus* A24 DNA was isolated and was toxic against our test insect. This clone was designated toxb4.

The recombinant plasmids from toxb4 and three further (non-toxic) deletion clones, toxb5, toxb6 and toxb7, were isolated and used for obtaining the sequence of both strands of the toxin gene. Sequencing was performed using the Applied Biosystems, Incorporated Model 370 automated sequencer. Sequencing templates were prepared using double stranded DNA templates and the 21M13 and SP6 primer sites located on the pGEM7Z(f)+ plasmid and

using the Taq dye primer cycle sequencing protocol (Applied Biosystems, Incorporated).

The toxin gene was found to consist of an 834 basepair open reading frame (Table 1) which translates into a 278 amino acid protein (Table 2). The start of the toxin gene sequence was preceded by appropriate DNA promoters necessary for transcription of the gene into a mRNA molecule prior to its synthesis into a peptide. These consist of a Shine-Dalgarno poly-purine sequence and -10 and -35 RNA polymerase recognition sequences (Table 1).

The DNA sequence and the derived amino acid sequences were analysed by sequence data bank analyses to determine if any other related sequences have previously been identified. The results indicated that no other sequence exists in the GenBank and EMBL data banks which has any similarity to this gene and its product.

Cloning of Xenorhabdus Toxin into a High-Expression Vector

Using the determined DNA sequence, 20-mer DNA primers were designed to cover the 5' and 3' region of the toxin gene and thus allow PCR amplification of the toxin and subsequent insertion into an expression vector. These primers included linker regions containing appropriate restriction enzyme sites (ClaI and NdeI for the 5' primer and Bam HI for the 3' primer).

5' primer CCATCGATCATATGGTTATTAAACC

3' primer CGGGATCCTTATCTCTAAGGTTTTT

Utilising a standard PCR protocol (Innis, M.A., Gelford, D.H., Sminsky, J.J. and White, T.J.: (1990). PCR Protocols : A Guide to Methods and Applications. Academic Press, San Diego. 482pp) the toxin was amplified out of the genome of *X.nematophilus* A24 and restriction digested with Cla I and Bam HI. The digested fragment was subsequently ligated into pGEM-7Zf(+) and then subcloned from this vector into the high expression vector pT7T2b(derived from pET11 [Novagen] and carrying the T7

promoter upstream from the start of the toxin insert; constructed by Dr. Karl Gordon, CSIRO, Division of Entomology) using the restriction enzyme sites Nde I and Bam HI. The recombinant plasmid was transformed into the
5 E. coli strain BL21(DE3)[F-ompT r_B - m_B -, which carries in its chromosome the T7 RNA polymerase gene under lac UV5 control). Induction of the toxin may be achieved by the addition of 0.4mM IPTG at mid-exponential phase of the culture and continuing the incubation for an extra 4
10 hours.

In vitro expression of the 1.2 Kb insert fragment from *toxb4* was achieved with the *E. coli* S30 Extract Procaryotic Translation System for linear DNA. Only a 30kDa peptide was produced indicating that the 1.2 Kb
15 fragment encodes one peptide only - the insect toxin.

Southern Blot Hybridization of a Range of *Xenorhabdus* spp. and *Photobabds* Luminescens Strains with the *X. nematophilus* A24 Toxin Gene

DNA isolated from a range of *Xenorhabdus* species and
20 *Photobabds* (bacteria symbiotically associated with nematodes from the family *Heterohabditidae*) controls was digested to completion with the restriction enzyme Eco RV and run out on a 0.8% TAE agarose gel and the DNA fragments blotted and fixed onto a Hybond-N+ membrane
25 (Amersham) as per the manufacturer's instructions.

The toxin gene was radiolabelled with ^{32}P using nick translation (Maniatis *et al.*, 1982) and probed against the blot containing the DNA of a range of *Xenorhabdus* and *Photobabds* strains (Maniatis *et al.*, 1982). Under
30 moderate stringency wash conditions at 65°C (0.1% SDS, 1% SSPE, Maniatis *et al.*, 1982) the toxin only hybridised to *X. nematophilus* and *X. beddingii* strains. However, the toxin gene did not show any homology to the DNA from strains of *X. bovienii*, *X. poinarii*, some unclassified
35 *Xenorhabdus* spp. and *Photobabds luminescens*. This result suggests that this toxin type is confined to strains from

the species *X. nematophilus* and *X. beddingii*. As *X. beddingii* has insecticidal activity and shows homology to the toxin gene it is most probable that these sequences are part of related/similar yet slightly different toxins.

- 5 A high stringency wash at 65°C (0.1% SDS, 0.1% SSPE; Maniatis et al. 1982) of the blot removed the message from the *X. beddingii* strain, but not from the *X. nematophilus* strains.

Characteristics of the Toxic Protein Product

- 10 The toxin is inactivated by heating to 65°C for 15 minutes, yet stable at 45°C. Sodium dodecyl sulphate at a concentration of 0.1% does not inactivate this toxin thereby indicating extreme stability and thereby a protein which will fold into its appropriate form under a wide
15 range of different conditions (which includes most cell types).

- This new class of toxin may be purified by one or more methods of protein purification well known in the art. Insecticidal fragments may be generated from the
20 purified toxin using, for example, cleavage with trypsin or cyanogen bromide.

- As will be appreciated by those skilled in this field, the present invention provides a new class of toxins useful for genetically engineering a wide range of
25 biological systems which will thus become more useful for control of insect pests detrimental to agricultural, aquatic and forest industries.

- It will be appreciated by persons skilled in the art that numerous variations and/or modifications may be made
30 to the invention as shown in the specific embodiments without departing from the spirit or scope of the invention as broadly described. The present embodiments are, therefore, to be considered in all respects as illustrative and not restrictive.

TABLE 1

1	AAGAAACCGT	AACAGCGGAA	ATCAACGCTG	CAATTTATAT	TAGTAGTCAT
				Start	-35
51	TTCAATAAAC	GCCAACATAA	TGGGAAAGTA	CAATGGTTAT	TAAACCCGTA
		-10	S-D		
101	ACAACTCCGA	GTGTAATACA	ATTAACGCCT	GATGATAGAG	TAACGCCTGA
151	TGATAAAGGT	GAATATCAAC	CCGTTGAAAA	GCAAATAGCG	GGAGATATAA
201	TACGTGTACT	AGAATTCAAG	CAAACAAATG	AAAGTCATAC	AGGATTGTAT
251	GGAATTCAT	ATCGAGCTAA	GAAAGTAATA	ATAGCATATG	CTTTAGCGGT
301	AAGTGGTATT	CATAATGTCT	CTCAACTTCC	AGAAGACTAT	TATAAAAATA
351	AGGATAACAC	AGGTAGAATT	TATCAAGTAT	ACATGTCTAA	TCTTTTATCT
401	GCACTATTGG	GTGAGAATGG	TGATCAAATT	TCTAAAGATA	TGGCAAATGA
451	TTTACCCAG	AACGAACTGG	AGTTTGAGGT	CAACGTCTTA	AAAATACCTG
501	GGATATTCTT	GATCTTGAGA	ATAAACTATT	GGAAGATTTA	TTCAGATGAA
551	GATAAATTAT	TAGCACTATA	TTTCTTTGCT	TCACAAGAAC	TTCCAATGGA
601	GGCAAATCAA	CAATCAAATG	CAGCAAAATT	TTTTAAAGTA	ATTGATTTTT
651	TACTTATCTT	ATCTGCTGTA	ACATCACTGG	GAAAAAGGAT	TTTTTCAAAA
701	AATTTTTACA	ATGGTCTAGA	AACTAAATCA	TTAGAGAATT	ATATTGAGAG
751	AAAAAACTT	TCTAAACCTT	TCTTTCGACC	ACCGCAGAAG	TTACCTGATG
801	GCAGAACAGG	CTACTTGGCC	GGTCCAACAA	AAGCGCCTAA	ATTGCCAACAA
851	ACGTCTTCTA	CAGCAACAAC	GTCTACAGCA	GCTTCATCTA	ATTGGAGAGT
901	TAGTTTGCAA	AAACCTTAGA	GATAACCCAT	CCAGAAATAC	ATTTATGAAA
		Stop			
951	ATGGATGATG	CTGCAAAACG	AAAATATAGT	TCATTTATAA	AAGAGGTACA
1001	AAAGGGTAAT	GATCCACGTG	CAGCAGCAGC	AAGTATTGGT	ACAAAAAGCG
1051	GCAGTAACTT	CGAAAACTG	CAAGGTAGAG	ATTTATATAG	TATAAGACTA
1101	AGCCAAGAAC	ACAGGGTAAC	ATTCTCCATA	AATAATACTG	ACCAAATAAT
1151	GGAGATCCAA	AGTGTTGGAA	CTCATTACCA	AAATATATAA	CCTGATTTAT
1201	AGTAGTGATA	AGACGTAAGA	TAAATATGGA	AGGTTGTAAT	TCTATTGCAC
1251	TTCTCAGAG	GTGACCGCTC	AG		

TABLE 2

1	MVIKPVTTPS VIQLTPDDR	TPDDKGEYQP	VEKQIAGDII	RVLEFKQTNE
51	SHTGLYGIPY RAKKVIIAYA	LAVSGIHNV	QLPEDYYKNK	DNTGRIYQVY
101	MSNLLSALLG ENGDQISKDM	ANDFTQNELE	FEVNVLKIPG	IFLILRINYW
151	KIYSDKLL ALYFFASQEL	PMEANQQSNA	ANFFKVIDFL	LILSAVTSLG
201	KRIFSKNFYN GLETKSLENY	IERKKLSKPF	FRPPQKLPDG	RTGYLAGPTK
251	APKLPTTSST ATTSTAASN	WRVSLOKPR	*PIQKYIYEN	G*CCKTKI*F
301	IYKRGTKG** STCSSSKYWY	KKRQ*LRKTA	R*RFI*YKTK	PRTQGNILHK
351	*Y*PNNGDPK CWNSLPKYIT	*FIVVIRRKI	NMEGCNSIAL	PQR*PL

CLAIMS:


1. A polynucleotide molecule comprising a nucleotide sequence which encodes an insecticidal toxin and which is at least 70% homologous to the nucleotide sequence shown in Table 1 from residue 83 to 919, or a fragment thereof which fragment encodes an insecticidal polypeptide.
2. A polynucleotide molecule as claimed in claim 1 in which the nucleotide sequence is at least 90% homologous to the nucleotide sequence shown in Table 1 from residue 83 to 919.
3. A polynucleotide molecule comprising a nucleotide sequence substantially corresponding to the sequence shown in Table 1 from residue 83 to 919 or a fragment thereof, which fragment encodes an insecticidal polypeptide.
4. A polynucleotide molecule according to claim 7, wherein the nucleotide sequence encodes an insecticidal toxin, or an insecticidal fragment thereof, from *Xenorhabdus nematophilus*
5. A polynucleotide nucleotide molecule according to any one of claims 1 to 4 in which the molecule is a DNA molecule.
6. A purified insecticidal toxin, or functional fragment thereof, from the bacterial genus *Xenorhabdus*.
7. A purified insecticidal toxin, or functional fragment thereof, from *Xenorhabdus nematophilus*.
8. An insecticidal toxin which includes an amino acid sequence which is at least 70% homologous to residues 1 to 278 shown in Table 2 or a functional fragment thereof.
9. An insecticidal toxin as claimed in claim 8 in which the toxin includes an amino acid sequence which is at least 90% homologous to residues 1 to 278 shown in Table 2 or a functional fragment thereof.
10. An insecticidal toxin, the toxin including an amino acid sequence substantially corresponding to residues 1 to 278 shown in Table 1 or a functional fragment thereof.

11. A recombinant organism characterised in that it is transformed with the polynucleotide molecule according to any one of claims 1 to 5.
12. A recombinant organism according to claim 10
5 selected from the group consisting of entomopoxvirus, nuclear polyhedrosis virus, bacteria, fungi, protozoa and plants.
13. A method for controlling the proliferation of insects, comprising applying to an infested area a
10 recombinant organism according to claim 10 or 11 optionally in admixture with an acceptable agricultural carrier.

AMENDED CLAIMS

[received by the International Bureau on 25 November 1994 (25.11.94); original claims 6 and 7 amended; remaining claims unchanged (1 page)]

1. A polynucleotide molecule comprising a nucleotide sequence which encodes an insecticidal toxin and which is at least 70% homologous to the nucleotide sequence shown in Table 1 from residue 83 to 919, or a fragment thereof which fragment encodes an insecticidal polypeptide.
2. A polynucleotide molecule as claimed in claim 1 in which the nucleotide sequence is at least 90% homologous to the nucleotide sequence shown in Table 1 from residue 83 to 919.
3. A polynucleotide molecule comprising a nucleotide sequence substantially corresponding to the sequence shown in Table 1 from residue 83 to 919 or a fragment thereof, which fragment encodes an insecticidal polypeptide.
4. A polynucleotide molecule according to claim 7, wherein the nucleotide sequence encodes an insecticidal toxin, or an insecticidal fragment thereof, from *Xenorhabdus nematophilus*.
5. A polynucleotide nucleotide molecule according to any one of claims 1 to 4 in which the molecule is a DNA molecule.
6. A purified insecticidal protein, or functional fragment thereof, from the bacterial genus *Xenorhabdus*.
7. A purified insecticidal protein, or functional fragment thereof, from *Xenorhabdus nematophilus*.
8. An insecticidal toxin which includes an amino acid sequence which is at least 70% homologous to residues 1 to 278 shown in Table 2 or a functional fragment thereof.
9. An insecticidal toxin as claimed in claim 8 in which the toxin includes an amino acid sequence which is at least 90% homologous to residues 1 to 278 shown in Table 2 or a functional fragment thereof.
10. An insecticidal toxin, the toxin including an amino acid sequence substantially corresponding to residues 1 to 278 shown in Table 1 or a functional fragment thereof.

A. CLASSIFICATION OF SUBJECT MATTER Int. Cl. ⁶ C12N 15/31, C12N 5/10, C12P 21/02, A01N 63/02 According to International Patent Classification (IPC) or to both national classification and IPC					
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) Derwent Database: file WPAT; Chemical Abstracts Service: file CASM. See "Electronic database" box for keywords.					
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched AU: C12N 15/31					
Electronic data base consulted during the international search (name of data base, and where practicable, search terms used) Derwent database, file WPAT; Chemical Abstracts service, file CASM; Keywords: "Xenorhabdus and (nematophilus or beddingii)"; "Akhurst" (in WPAT), "Akhurst and Xenorhab:" in CASM. STN International, file CA, sequence "CCGTTGAAAAGCAAA" and "PMEANQQSNA".					
C. DOCUMENTS CONSIDERED TO BE RELEVANT					
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to Claim N .			
X	AU,B,21230/83 (558287) (COMMONWEALTH SCIENTIFIC AND INDUSTRIAL ORGANISATION) 22 May 1984 (22.05.84) See entire specification especially page 3 lines 15-29.	6,7			
X	B.V. McINERNEY et al: "Biologically active metabolites from <u>Xenorhabdus</u> spp, Part 1. Dithiolopyrrolone derivatives with antibiotic activity". Journal of Natural Products, Vol. 54, number 3, pp. 774-784, May-June 1991. See abstract, page 779 last 2 paragraphs, page 780 Table 2, page 781 first paragraph	6,7			
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. </div> <div style="width: 45%;"> <input checked="" type="checkbox"/> See patent family annex. </div> </div>					
<table style="width: 100%; border: none;"> <tr> <td style="width: 30%; vertical-align: top;"> * Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed </td> <td style="width: 10%; vertical-align: top; text-align: center;"> "T" "X" "Y" "&" </td> <td style="width: 60%; vertical-align: top;"> later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art document member of the same patent family </td> </tr> </table>			* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" "X" "Y" "&"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art document member of the same patent family
* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" "X" "Y" "&"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art document member of the same patent family			
Date of the actual completion of the international search 6 September 1994 (06.09.94)		Date of mailing of the international search report 30 SEPTEMBER 1994 (30.09.94)			
Name and mailing address of the ISA/AU AUSTRALIAN INDUSTRIAL PROPERTY ORGANISATION PO BOX 200 WODEN ACT 2606 AUSTRALIA Facsimile No. (06) 2853929		Authorized officer <div style="text-align: center; font-family: cursive; font-size: 1.2em;">  </div> ROBYN PORTER Telephone N . (06) 2832318			

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate of the relevant passages	Relevant to Claim N .
X	B.V. McINERNEY et al: "Biologically active metabolites from <u>Xenorhabdus</u> spp. Part 2. Benzopyran-1-one derivatives with gastroprotective activity", Journal of Natural Products, Vol. 54, number 3, pp. 785-795, May-June 1991.	6,7

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report		Patent Family Member			
AU	21230/83	CA	1214130	EP	126092
		WO	84/01775	ZA	8307974
				US	4672130
END OF ANNEX					

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				